TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors.

Zhiwei CuiHaoyu SunZhishuang GaoChao LiTingting XiaoYibo BianZonghang LiuTianhao GuJianan ZhangTengyun LiQianzheng ZhouZhongyuan HeBowen LiFengyuan LiZekuan XuHao Xu

Published in: British journal of cancer (2024)

These findings demonstrate that the TRIM21 and USP15 control ACSL4 stability to maintain the IM sensitive/resistant status of GIST.

Keyphrases